Tagrisso approved in China as a 1st-line treatment for EGFR-mutated non-small cell lung cancer
4 September 2019 07:00 BST Tagrisso approved in China as a 1st-line treatment for EGFR-mutated non-small cell lung cancer In the Phase III FLAURA trial, Tagrisso significantly increased thetime patients lived without disease progression versus the comparator Tagrisso is the only medicine demonstrating statistically-significantoverall survival benefit in this setting AstraZeneca today announced that it has received marketing authorisation from China's National Medical Products Administration (NMPA) for Tagrisso (osimertinib) as a 1st-line treatment for adults with locally-